Header cover image
  • Investing Ideas
  • Australian Pharmaceuticals & Biotech Large Cap High Growth Potential

Australian Pharmaceuticals & Biotech Large Cap High Growth Potential

Results

1

0 new

Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.

1 companies

CSL

Market Cap: AU$48.4b

Engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.

CSL

AU$98.47

7D

2.3%

1Y

-60.1%